IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

nivolumab and relatlimab-rmbw injection

nivolumab and relatlimab-rmbw injection
for intravenous use Initial U.S. Approval: 2022

Opdualag is a premixed combination of nivolumab and relatlimab that is prepared and given through intravenous (IV) infusions. Opdualag is a prescription medicine used to treat adults who have a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma) and children who are 12 years of age and older, who have melanoma that has spread or cannot be removed by surgery (advanced melanoma).

Facts about nivolumab and relatlimab-rmbw injection

Approval Date: 3/18/2022
Proprietary Name: Opdualag
Active Ingredient(s): nivolumab and relatlimab-rmbw
FDA-approved use: To treat unresectable or metastatic melanoma
Dosage Form: Injection
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “nivolumab and relatlimab-rmbw injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For nivolumab and relatlimab-rmbw injection

Approved accessible "nivolumab and relatlimab-rmbw injection"

OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

OPDUALAG is a prescription medicine used to treat: • adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery. It is not known if OPDUALAG is safe and effective when used: • in children 12 years of age or older who weigh less than 88 pounds (40 kg), or • in children younger than 12 years of age. Active ingredients: nivolumab and relatlimab Reference ID: 4955315Inactive ingredients: Water for Injection.

How can 1 go about obtaining nivolumab and relatlimab-rmbw injection?

If nivolumab and relatlimab-rmbw injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

OPDUALAG (nivolumab and relatlimab-rmbw) injection, for intravenous use Initial U.S. Approval: 2022


  • For OPDUALAG (nivolumab and relatlimab-rmbw)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details 
  • Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma For More Details 
  • Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma For More Details 

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398